Company Profile
AnaptysBio, Inc. Stock Price, News & Analysis
- Ticker:
- ANAB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
54.77 USD (-0.40%)
Close
Last updated: August 6, 2026
1.49B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ANAB closed down 0.40% at $54.77. No new same-company headline was identified in the current news window.
Company overview
Biopharma Royalty Company
Following the spin-off of First Tracks Biotherapeutics, AnaptysBio manages financial collaborations rather than operating an internal drug-development portfolio.
Jemperli Economics
Anaptys receives royalties tied to GSK’s Jemperli franchise, including development in endometrial, rectal, colon, and head and neck cancers.
Imsidolimab Economics
The company also retains financial exposure to Vanda’s imsidolimab program in generalized pustular psoriasis.
Future catalysts
Data from the pivotal AZUR-1 study of Jemperli in locally advanced rectal cancer are expected in the second half of 2026.
Data from the Phase 2 AZUR-4 colon cancer study are expected in the fourth quarter of 2026.
The FDA PDUFA action date for imsidolimab in generalized pustular psoriasis is December 12, 2026.
Recent news
- 01
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
Source: AnaptysBio, Inc.
- 02
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
Source: AnaptysBio, Inc.
- 03
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
Source: AnaptysBio, Inc.
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of AnaptysBio, Inc. (ANAB)?
AnaptysBio, Inc. (ANAB) most recently closed at 54.77 USD, a -0.40% move versus the previous session.
What is the market cap of AnaptysBio, Inc. (ANAB)?
AnaptysBio, Inc. currently has a market capitalization of 1.49B USD on BioPharmSignal.
What does AnaptysBio, Inc. do?
Biopharma Royalty Company Following the spin-off of First Tracks Biotherapeutics, AnaptysBio manages financial collaborations rather than operating an internal drug-development portfolio. Jemperli Economics Anaptys receives royalties tied to GSK’s Jemperli franchise, including development in endometrial, rectal, colon, and head and neck cancers. Imsidolimab...
On which exchange is ANAB stock listed?
AnaptysBio, Inc. (ANAB) is associated with NASDAQ, United States, Biopharma.
What is AZUR-1?
Data from the pivotal AZUR-1 study of Jemperli in locally advanced rectal cancer are expected in the second half of 2026.
Which conditions is AnaptysBio, Inc. targeting with AZUR-1?
AnaptysBio, Inc. is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does AnaptysBio, Inc. describe recent progress with AZUR-1?
Data from the pivotal AZUR-1 study of Jemperli in locally advanced rectal cancer are expected in the second half of 2026.
What is AZUR-4?
Data from the Phase 2 AZUR-4 colon cancer study are expected in the fourth quarter of 2026.